Analysis of the Abscopal Effect with Anti-PD1 Therapy in Patients with Metastatic Solid Tumors

Journal of Immunotherapy

Volumn 39, Issue 9, 2016, Pages 367-372

  Gomes, Jéssica Ribeiro ^a   Schmerling, Rafael A ^a   Haddad, Carolina K ^a   Racy, Douglas J ^a   Ferrigno, Robson ^a   Gil, Erlon ^a   Zanuncio, Pedro ^a   Buzaid, Antônio C ^a  

^a Antonio Ermirio de Moraes Oncology Center   (Brazil)

Author keywords

abscopal effect; anti PD1; melanoma; metastatic solid tumors; radiotherapy

Indexed keywords

B RAF KINASE INHIBITOR; BEVACIZUMAB; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; NIVOLUMAB; PEGINTERFERON; PEMBROLIZUMAB; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CHOROID MELANOMA; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; CUTANEOUS MELANOMA; DISTANT METASTASIS; FEMALE; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; LUNG ADENOCARCINOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MELANOMA; METASTASIS; METASTATIC MELANOMA; MUCOSAL MELANOMA; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; RADIATION DOSE; RETROSPECTIVE STUDY; SOLID TUMOR; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR REGRESSION; BRAZIL; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY TUMOR; LUNG; LYMPH NODE; MIDDLE AGED; PATHOLOGY; PROCEDURES; RADIATION RESPONSE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAZIL; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; LUNG; LYMPH NODES; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PROGRAMMED CELL DEATH 1 RECEPTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84992206485     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000141     Document Type: Article

References (30)

1. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372: 2521-2532.
2. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Eng J Med. 2015;372:320-330.
3. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Eng J Med. 2015;373:23-34.
4. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Eng J Med. 2010;363:711-723.
5. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908-918.
6. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375-384.
7. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123-135.
8. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627-1639.
9. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 Blockade with nivolumab in relapsed or refractory hodgkin's lymphoma. N Engl J Med. 2015;372:311-319.
10. Motzer RJ, Escudier B, McDermott D, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803-1813.
11. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889-1894.
12. Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Eng J Med. 2012;366:925-931.
13. Mole R. Whole body irradiation therapy - radiobiology or medicine? Br J Radiol. 1953:234-241.
14. Andrews JR. Radiobiology of Human Cancer Radiotherapy, 2nd ed. Baltimore, MD: University Park Press; 1978.
15. Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol. 2009;10:718-726.
16. Gameiro SR, Jammeh ML, Wattenberg MM, et al. Radiationinduced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget. 2014;5:403-416.
17. Sharabi AB, Lim M, DeWeese TL, et al. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015;16: e498-e509.
18. Grimaldi AM, Simeone E, Giannarelli D, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology. 2014;3:e28780-1-e28780-9.
19. Chandra RA, Wilhite TJ, Balboni TA, et al. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology. 2015;4:e1046028-1-e1046028-7.
20. Seung SK, Curti BD, Crittenden M, et al. Phase 1 study of stereotactic body radiotherapy and interleukin-2 - tumor and immunological responses. Sci Transl Med. 2012;4: 137ra74-1-137ra74-1-7.
21. Demaria S, Kawashima N, Yang AM, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 2005;11(pt1):728-734.
22. Polistena A, Johnson LB, Ohiami-Masseron S, et al. Local radiotherapy of exposed murine small bowel: apoptosis and inflamation. BMC Surg. 2008;8:1-7.
23. Zeng J, See AP, Phalen J, et al. Anti-PD1 blockade and stereotatic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86: 343-349.
24. Hiniker SM, Chen DS, Reddy S, et al. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Trans Oncol. 2012;5:404-407.
25. Golden EB, Demaria S, Schiff PB, et al. An abscopal response to radiation and ipilimumab in a patient with metastatic nonsmall cell lung cancer. Cancer Immunol Res. 2013;1:365-372.
26. Sullivan RJ, Lawrence DP, Wargo JA, et al. Case records of the Massachusetts General Hospital. Case 21-2013. A 68-yearold man with metastatic melanoma. N Engl J Med. 2013;369: 173-183.
27. Deng L, Liang H, Burnette B, et al. Irradiation and anti-PDL1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124:687-695.
28. Golden EB, Chhabra A, Chachoua A, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015; 16:795-803.
29. Hodi FS, Hwu WJ, Kefford R, et al. Evaluation of immunerelated response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 2016;34:1510-1517.
30. Barker CA, Postow MA, Khan SA, et al. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res. 2013;1:92-98.